Research Article
Bevacizumab as Adjuvant Therapy in the Treatment of Keloid: A Randomized Clinical Trial
Table 1
Baseline characteristics of the study patients by treatment group.
| | | Total (n = 38) | TriamHEXAL (n = 19) | TriamHEXAL + Avastin (n = 19) | | | Mean | SD | Mean | SD | Mean | SD |
| | Age (yr) | 35.32 | 14.02 | 38.00 | 15.38 | 32.63 | 12.34 | 0.243 | | | | | | | | | | | BMI (kg/m2) | 27.37 | 3.60 | 27.84 | 3.70 | 26.89 | 3.53 | 1.000 | | Duration of disease (month) | 22.74 | 13.96 | 22.74 | 12.42 | 22.74 | 15.69 | 0.424 |
| | | N | % | N | % | N | % | |
| | Gender | | | | | | | | | Male | 19 | 50% | 10 | 52.6% | 9 | 47.4% | 0.746 | | Female | 19 | 50% | 9 | 47.4% | 10 | 52.6% | |
| | Cause | | | | | | | | | Acne | 15 | 39.5% | 8 | 53.3% | 7 | 46.7% | 0.740 | | Surgery | 17 | 44.7% | 7 | 41.2% | 10 | 58.8% | | | Burning | 4 | 10.5% | 3 | 75.0% | 1 | 25.0% | | | Accident | 2 | 5.3% | 1 | 50.0% | 1 | 50.0% | |
| | Family history | | | | | | | | | No | 31 | 81.6% | 15 | 48.4% | 16 | 51.6% | 1.000 | | Yes | 7 | 18.4% | 4 | 57.1% | 3 | 42.9% | |
| | Site | | | | | | | | | Trunk | 21 | 55.3% | 10 | 47.6% | 11 | 52.4% | 0.744 | | Extremities | 17 | 44.7% | 9 | 52.9% | 8 | 47.1% | |
|
|
